Affimed (AFMD) has released an update.
At the 2024 Annual General Meeting, shareholders of Affimed N.V., a biopharmaceutical company, overwhelmingly approved all agenda items, including the adoption of the 2023 statutory annual accounts, the discharge of managing and supervisory directors for the previous year, and the reappointment of multiple directors. Additionally, the company received approval for the increase of authorized share capital, authorization for the Management Board to issue shares and grant rights to subscribe for shares, and the appointment of an auditor for the financial year 2024.
For further insights into AFMD stock, check out TipRanks’ Stock Analysis page.
